InsidersTradesSigma
Sino Biopharmaceutical Ltd.: directors' dealings · Hong Kong · HKEX
HKEX:sino-biopharmaceutical-ltdHK·HKEXMcap 94.6Bn€Healthcare
Explore the full directors' dealings record of Sino Biopharmaceutical Ltd., a listed issuer based in Hong Kong. Shares are quoted on HK HK, under the oversight of HKEX. Operating in the Healthcare sector, Sino Biopharmaceutical Ltd. has logged 6 public disclosures. Market capitalisation: €94.6bn. The latest transaction was reported on 30 April 2026 (Purchase). Among the most active insiders: Cheng Cheung Ling. The full history is free.
6
Insider Decl.
0
Thresholds
€8m
6 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
5.30 €
Analyst consensus
19 analystsStrong buy
7.11 €Target 8.87 €(+67%)10.54 €
Income statement
Revenue31.83 Bn€
Gross profit26.13 Bn€82% margin
Net income2.34 Bn€7.4% margin
Valuation
PER (trailing)35.3x
PER (forward)19.8x
P/Book2.7x
Beta0.64
Balance sheet & cash
Market cap94.60 Bn€
Total debt16.07 Bn€
Free Cash Flow7.59 Bn€
Debt / Equity38%
Profitability & ownership
ROE12.5%
ROA5.6%
% insiders48.5%
% institutions20.6%
Last declaration on 30 April 2026
Declarations6 total
Executives●Purchase9HKEX
€592,0681,000,000 shares@ €0.59210.0006% mcap20.0% of flow
ShareXHKG
HKEX:DA20260430E00374·
Ideal exit: 25 Jan 2027 (T+270)
Executives●Purchase9HKEX
€597,2801,000,000 shares@ €0.59730.0006% mcap20.2% of flow
ShareXHKG
HKEX:DA20260429E00338·
Ideal exit: 24 Jan 2027 (T+270)
Executives●Purchase13HKEX
€2m3,000,000 shares@ €0.59120.0019% mcap59.9% of flow
ShareXHKG
HKEX:DA20260428E00209·
Ideal exit: 23 Jan 2027 (T+270)
Executives●Purchase15HKEX
€1m1,748,000 shares@ €0.6380.0012% mcap100.0% of flow
ShareXHKG
HKEX:DA20260330E00223·
Ideal exit: 25 Dec 2026 (T+270)
6 of 6 declarations